114种新药落地报销 甘肃新版医保药品目录全面执行

Core Viewpoint - The implementation of the new medical insurance drug directory in Gansu Province aims to enhance healthcare accessibility by including 114 urgently needed drugs, with a focus on innovative treatments and chronic disease management [1][2]. Group 1: New Drug Inclusion - A total of 114 new drugs have been added to the medical insurance reimbursement list, with 50 being innovative drugs, marking a record high in both quantity and proportion [2]. - Among the new additions, 36 are anti-cancer drugs targeting various types of cancers, significantly reducing patient costs; for instance, the price of a domestic innovative drug for triple-negative breast cancer drops from nearly 10,000 yuan to over 4,000 yuan after insurance reimbursement [2]. - The total number of drugs in the Gansu medical insurance directory has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines, while 29 low-value drugs have been removed to optimize fund allocation [2]. Group 2: Commercial Insurance Innovations - The first edition of the Commercial Health Insurance Innovative Drug Directory has been launched, including 19 high-value innovative drugs that complement basic medical insurance [3]. - These drugs cover critical areas such as cancer and rare diseases, encouraging commercial insurance companies to design new products and improve reimbursement scopes [3]. Group 3: Implementation Measures - Gansu Province has upgraded its medical insurance information system to ensure smooth reimbursement processes and accurate drug directory updates [4]. - Measures include classifying high-demand drugs for separate payment policies to reduce patient financial burdens and a 6-month transition period for drugs that are not renewed in the directory [4]. - Ongoing training and monitoring will be conducted to ensure that medical institutions comply with the new policies and that patient medication needs are met while safeguarding the insurance fund [4].